×
Back to Agenda
Benchmarking and Identifying Opportunities to Improve Intentional Dose Non-Adherence in Clinical Trials
Session Chair(s)
Kenneth Getz, MBA
Tufts Center for the Study of Drug Development, Tufts University School of Medicine, United States
The results of a groundbreaking study quantifying intentional dose non-adherence are presented followed by a discussion among a panel of clinical and regulatory professionals on the implications of the findings.
Learning Objective : Quantify intentional dose non-adherence rates in clinical trials; Identify factors associated with, and predictive of intentional non-adherence; Discuss policies and solutions to address and reduce intentional non-adherence.
Speaker(s)
Quantifying the Magnitude of Intentional Dose Non Adherence
Tufts Center for the Study of Drug Development, Tufts University School of Medicine, United States
Accounting For and Managing Dose Non-Adherence in Clinical Trials
Vice President, Product Management, AiCure, United States
Have an account?